Found: 4
Select item for more details and to access through your institution.
Cabozantinib plus docetaxel and prednisone in metastatic castration‐resistant prostate cancer.
- Published in:
- BJU International, 2021, v. 127, n. 4, p. 435, doi. 10.1111/bju.15227
- By:
- Publication type:
- Article
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
- Published in:
- BJU International, 2016, v. 118, n. 4, p. 590, doi. 10.1111/bju.13412
- By:
- Publication type:
- Article
A Prospective Comparison of <sup>18</sup>F-Sodium Fluoride PET/CT and PSMA-Targeted <sup>18</sup>F-DCFBC PET/CT in Metastatic Prostate Cancer.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 11, p. 1665, doi. 10.2967/jnumed.117.207373
- By:
- Publication type:
- Article
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer.
- Published in:
- Oncologist, 2023, v. 28, n. 7, p. 642, doi. 10.1093/oncolo/oyad058
- By:
- Publication type:
- Article